Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study.
The Gynecologic Oncology Group performed a Phase II study to determine the response rate of pyrazoloacridine (PZA) in patients with platinum-resistant ovarian cancer. PZA was administered at a dose of 750 mg/m2 intravenously over 3 hours every 3 weeks. Among 24 evaluable patients, there was 1 (4.2%) complete and 1 (4.2%) partial response. The major toxicities were hematologic. With the dose and schedule used, PZA had only modest activity in this population.
Plaxe
Steven C
SC
Department of Reproductive Medicine, Division of Gynecologic Oncology, University of California-San Diego Medical Center, 402 Dickinson Street, San Diego, CA 92103-8433, U.S.A.
Blessing
John A
JA
Morgan
Mark A
MA
Carlson
John
J
D000166:Acridines / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011720:Pyrazoles / Q000008:administration & dosage / Q000627:therapeutic use*
D000166:Acridines; D000970:Antineoplastic Agents; D011720:Pyrazoles; D016190:Carboplatin; C064541:NSC 366140; D002945:Cisplatin